Table 2.
Effects of Magnesium Citrate, Magnesium Oxide, and Magnesium Sulfate (Versus Placebo) on Vascular Function Markers
|
Magnesium citrate (n=46) |
Magnesium oxide (n=46) |
Magnesium sulfate (n=46) |
Placebo (n=26) |
|
|---|---|---|---|---|
| c‐fPWV | ||||
| 2‐wk | ||||
| Mean, m/s | 9.1±1.9 | 8.5±1.4 | 8.4±1.4 | 8.4±1.9 |
| Difference vs placebo | 0.2 (−0.5 to 0.8) | 0.2 (−0.4 to 0.9) | −0.2 (−0.9 to 0.4) | … |
| 12‐wk | ||||
| Mean, m/s | 9.0±1.9 | 8.5±1.2 | 8.7±1.7 | 8.5±1.5 |
| Difference vs placebo | 0.0 (−0.6 to 0.7) | −0.0 (−0.7 to 0.6) | −0.0 (−0.7 to 0.6) | … |
| 24‐wk | ||||
| Mean, m/s | 9.0±1.6 | 8.4±1.6 | 8.3±1.4 | 8.5±2.3 |
| Difference vs placebo | −0.0 (−0.7 to 0.6) | −0.0 (−0.6 to 0.6) | −0.3 (−1.0 to 0.3) | … |
| AI@HR75 | ||||
| 2‐wk | ||||
| Mean, % | 25.0±8.5 | 21.7±8.6 | 23.4±8.5 | 22.9±10.8 |
| Difference vs placebo | −1.1 (−3.4 to 1.2) | −0.6 (−3.0 to 1.8) | −0.3 (−0.6 to 2.0) | … |
| 12‐wk | ||||
| Mean, % | 25.3±8.4 | 20.8±9.0 | 23.3±9.1 | 21.5±10.0 |
| Difference vs placebo | 0.7 (−1.7 to 3.0) | 0.1 (−2.2 to 2.5) | 0.7 (−1.6 to 3.0) | … |
| 24‐wk | ||||
| Mean, % | 24.7±8.9 | 21.3±8.3 | 23.9±9.1 | 22.4±10.4 |
| Difference vs placebo | −1.0 (−3.3 to 1.4) | −0.1 (−2.5 to 2.2) | 0.5 (−1.8 to 2.8) | … |
Values are mean±SD. Adjusted mean differences (95% CIs) were obtained from linear mixed‐effect models with age, sex, baseline value of the outcome of interest, time, intervention, and the interaction time×intervention as fixed effects. AI@HR75 indicates augmentation index adjusted for heart rate; and c‐fPWV; carotid‐to‐femoral pulse wave velocity.